CGRP
46 programs · 44 companies
Programs
46
Companies
44
Active Trials
40
Targeting CGRP
| Drug | Company | Phase | MOA | Indications |
|---|---|---|---|---|
| TAK-9344 | Takeda | Phase 3 | ThymomaOCD | |
| Zenotinib | BioNTech | Phase 1 | MCLGIST | |
| Capiglumide | BioNTech | Preclinical | Asthma | |
| BII-4342 | Biogen | Phase 2/3 | IgANRSV | |
| LEG-9870 | Legend Biotech | Phase 1 | WM | |
| ASN-4879 | Ascendis Pharma | Phase 3 | PSPPompe | |
| MDG-611 | Madrigal Pharma | Approved | Endometrial CaAS | |
| ZYM-7428 | Zymeworks | Phase 1/2 | RCC | |
| Surarelsin | Stoke Ther | Phase 3 | Cervical Ca | |
| Tezeratamab | Prime Medicine | Phase 3 | AsthmaThymoma | |
| EXA-971 | Exscientia | Phase 2 | Urothelial CaACC | |
| TEM-4581 | Tempus AI | Phase 2/3 | MCLNarcolepsy | |
| Doxaosocimab | Ascletis | Phase 1/2 | NMOSDPsoriasis | |
| EOR-IIT-541 | EORTC | Phase 2/3 | RSV | |
| NCI-IIT-396 | NCI Canada | Approved | CML | |
| Adagrazumab | Deerfield Mgmt | Phase 3 | NMOSDSCLC | |
| Daranesiran | Atlas Venture | Phase 2/3 | CholangiocarcinomaMDD | |
| Bemarelsin | Maze Ther | Phase 2/3 | HNSCCLGS | |
| CIR-5071 | Cirius Therapeutics | Phase 2 | MS | |
| NOR-5927 | NorthStar Medical | Phase 1 | Epilepsy | |
| ALL-5401 | Allergan (AbbVie) | NDA/BLA | DMD | |
| SHI-1915 | Shire (Takeda) | Phase 2 | Myelofibrosis | |
| 116-3223 | Jacobio | Phase 2 | PNH | |
| INS-3736 | Insitro | Phase 1 | Crohn's | |
| CEL-9671 | Cellarity | NDA/BLA | PSP | |
| Olpanaritide | BioHaven (Pfizer) | Phase 2/3 | HNSCCHemophilia A | |
| RYT-9424 | Rhythm Pharma | Phase 2/3 | Endometrial CaGBM | |
| SCR-7300 | Scribe Ther | NDA/BLA | CLL | |
| ASK-539 | Askbio (Bayer) | NDA/BLA | MG | |
| Zorivorutinib | PeptiDream | NDA/BLA | CMLCKD | |
| 003-1437 | Boryung | Phase 2 | RA | |
| BIO-8650 | Biocon | Phase 2 | NASH | |
| Mavuderotide | Piramal Pharma | Preclinical | ObesityMM | |
| RNA-5263 | Avidity Bio | Phase 1/2 | AS | |
| Ivonesiran | Laboratorios Rovi | Phase 1/2 | ObesityADPKD | |
| 028-9914 | HLB Inc | NDA/BLA | CeliacPBC | |
| Datozanubrutinib | Hanmi Pharm | Phase 2 | Hemophilia A | |
| Surasertib | Wockhardt | Phase 1/2 | ADPKD | |
| Mavulucimab | Tecnoquimicas | NDA/BLA | Hemophilia A | |
| Kemalucimab | Julphar | Phase 2/3 | CeliacMCL | |
| RUI-IIT-588 | Ruijin Hospital | NDA/BLA | PNH | |
| RUI-IIT-706 | Ruijin Hospital | NDA/BLA | ALS | |
| SEV-IIT-392 | Severance Hospital | NDA/BLA | Atopic Derm | |
| 300-6128 | Zhifei Biological | NDA/BLA | PBC | |
| Riboinavolisib | Sorriso Pharma | Phase 1/2 | DMD | |
| IDX-6209 | IDEXX Laboratories | Preclinical | CRC |